Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.42 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 11/20 | 0.60 |
| ▸ | TDP2 | O95551 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539077 | 0.99 | PGR (0.61) | PGRTDP2MAPTIDO1TSHR | |
| SCHEMBL6541741 | 0.99 | PGR (0.61) | PGRTDP2MAPTIDO1TSHR | |
| SCHEMBL6540904 | 0.99 | PGR (0.61) | PGRTDP2MAPTIDO1TSHR | |
| SCHEMBL7190173 | 0.92 | PGR (0.54) | PGRTDP2 | |
| SCHEMBL6539880 | 0.84 | PGR (0.56) | PGRTDP2MAPTIDO1TDP1 | |
| SCHEMBL9176307 | 0.83 | ALDH1A1 (0.45) | PGRMAPTTSHRACHETDP1 | |
| SCHEMBL7179210 | 0.79 | PGR (0.51) | PGRTDP2MAPTSMN1; SMN2 | |
| SCHEMBL6540131 | 0.77 | PGR (0.58) | PGRTDP2MAPTIDO1 | |
| Hydrochloric Acid SCHEMBL27558602 | 0.77 | PGR (0.54) | PGRTDP2MAPTIDO1TDP1 | |
| SCHEMBL15497921 | 0.75 | ALDH1A1 (0.44) | PGRTDP2MAPTTSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175397-B1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | WYETH CORP (US) | 2004-08-18 | — | — | EP | claimed |
| US-6503939-B2 | That are antagonists of the progesterone receptor, in a female contraceptive kit | WYETH | 2003-01-07 | — | — | US | claimed |
| JP-2002543157-A | — | — | 2002-12-17 | — | — | JP | claimed |
| JP-2002543181-A | — | — | 2002-12-17 | — | — | JP | claimed |
| US-6417214-B1 | COMPOUNDS AS CONTRACEPTIVES | WYETH | 2002-07-09 | — | — | US | claimed |
| EP-1175397-A1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-01-30 | — | — | EP | claimed |
| EP-1173211-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | claimed |
| US-6329416-B1 | ADMINISTERING TO FEMALE OF CHILD BEARING AGE FOR 28 CONSECUTIVE DAYS: FIRST PHASE DOSAGE OF PROGESTATIONAL AGENT; SECOND PHASE OF ANTIPROGESIN COMPOUND, AND THIRD PHASE OF PLACEBO FOR CONTRACEPTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-11 | — | — | US | claimed |
| WO-2000066554-A1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | claimed |
| WO-2000066166-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | claimed |
| US-6835744-B2 | For therapy of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of endometrium, ovary, breast, colon, prostate, pituitary, meningioma and other hormone-dependent tumors | WYETH | 2004-12-28 | — | — | US | disclosed |
| EP-1175397-B1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | WYETH CORP (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030008909-A1 | 3,3-substituted indoline derivatives | WYETH (US) | 2003-01-09 | — | — | US | disclosed |
| US-6503939-B2 | That are antagonists of the progesterone receptor, in a female contraceptive kit | WYETH | 2003-01-07 | — | — | US | disclosed |
| US-6417214-B1 | COMPOUNDS AS CONTRACEPTIVES | WYETH | 2002-07-09 | — | — | US | disclosed |
| EP-1175397-A1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-1173211-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6329416-B1 | ADMINISTERING TO FEMALE OF CHILD BEARING AGE FOR 28 CONSECUTIVE DAYS: FIRST PHASE DOSAGE OF PROGESTATIONAL AGENT; SECOND PHASE OF ANTIPROGESIN COMPOUND, AND THIRD PHASE OF PLACEBO FOR CONTRACEPTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-11 | — | — | US | disclosed |
| WO-2000066554-A1 | 3,3-SUBSTITUTED INDOLINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066166-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008909-A1 | 3,3-substituted indoline derivatives | NR3C2, PGR, HTR3C | ACHE 2326/4885MMP8 4724/4885PGR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.